Michael S. Feld Biophotonics Award

Established in 2012, the Michael S. Feld Biophotonics Award recognizes individuals for their innovative and influential contributions to the field of biophotonics, regardless of their career stage. The scope of the award encompasses all areas of biophotonics ranging from fundamental optics discoveries in biology to development of new theoretical frameworks and novel instrumentation to clinical translational research for biomedicine.

Help Fund the Award
The Michael S. Feld Biophotonics Award will honor Prof. Michael Feld for his fundamental contributions in the fields of laser science and applied physics to solving biomedical problems. Consider making a contribution today.

About Professor Feld
Feld founded the Laser Biomedical Research Center at MIT in 1985 with support of the National Institutes of Health, where he directed research on the use of fluorescence and Raman spectroscopy to diagnose biological tissues and image disease via endoscopy and optical tomography. His accomplishments in this field included pioneering work on the use of Raman spectroscopy for analysis of biological tissues (1991), leading to clinical applications in non-invasive glucose measurement (2002), diagnosing altherosclerosis and detecting breast cancer (2006).

His work in tissue spectroscopy included advancing diffuse reflectance for isolating the intrinsic fluorescence of tissue (1993) and detecting precancerous changes in the colon (1999). His group introduced the use of light scattering spectroscopy for measuring cell nuclei in (1998) and demonstrated detection of precancerous changes in the esophagus, colon and cervix (2000). The combination of these techniques, termed tri-modal spectroscopy, were shown by his group to be highly diagnostic of precancerous changes in the esophagus (2001), cervix (2002) and oral cavity (2003).

Call for Nominations
Nominations are initiated by OSA members and are reviewed by a committee of topic experts whose recommendations are submitted to the OSA Awards Committee. Ultimate approval is by the OSA Board of Directors.